• No image available for this medication

    • MARAVIROC (Generic for SELZENTRY)

    • QTY 60
    • 300 MG
    • Tablet

MARAVIROC (mah RAV er rock) is an antiretroviral medicine. It is used with other medicines to treat HIV. This medicine is not a cure for HIV. This medicine can lower, but not fully prevent, the risk of spreading HIV to others.

MARAVIROC (Generic for SELZENTRY) Lifestyle Interactions

  • Maraviroc 300mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: It is best to avoid Grapefruit or Grapefruit Juice while taking Maraviroc. Side effects from Maraviroc may get worse. Notify your health care provider if you experience chest pain, symptoms of infection, rash, symptoms of potential liver problems, or other new or unusual side effects.
    • Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice during maraviroc therapy. Coadministration of maraviroc, a CYP3A substrate, with grapefruit juice, a strong CYP3A4 inhibitor, may result in increased maraviroc concentrations and increased side effects. Reduce the dose of maraviroc when it is used with other strong CYP3A inhibitors; coadministration of maraviroc with strong CYP3A inhibitors is contraindicated in patients with CrCl less than 30 mL/minute.

  • Maraviroc 300mg, Oral tablet

    • Interaction: Alcohol
    • Severity: Mild
    • Notes for Consumers: Do not stop taking Maraviroc when alcohol is ingested. Missing doses or stopping treatment can create resistance of the virus to treatment. While alcohol concentrations may increase, there is not an adverse effect on your antiviral treatment. You may feel experience alcohol side effects like feeling more drowsy or some nausea. Do not drive or operate machinery, or perform other hazardous tasks when you choose to consume alcohol.
    • Notes for Professionals: Maraviroc treatment should not be interrupted if alcohol is consumed. Counsel patients to continue their antiviral treatment to avoid potential for viral resistance. In a pharmacokinetic study, healthy adults were administered alcohol (1 gram/kg) and placebo, with data collected before and after 7 days of maraviroc administration. Alcohol concentrations increased by 12% when patients were taking maraviroc. Adverse symptoms were mild and included increased drowsiness and nausea during sessions of alcohol administration. Maraviroc pharmacokinetics were unaffected by alcohol.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.